Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis> A study of IgG subclasses and clinical correlations

Journal of Neuroimmunology

Volumn 111, Issue 1-2, 2000, Pages 169-176

  Romi, Fredrik ^a   Skeie, Geir Olve ^a   Vedeler, Christian ^a   Aarli, Johan A ^a   Zorzato, Francesco ^b   Gilhus, Nils Erik ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Complement activation; IgG subclasses; Myasthenia gravis; Ryanodine receptor antibodies; Titin antibodies

Indexed keywords

AUTOANTIBODY; CONNECTIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MUSCLE PROTEIN; RECEPTOR ANTIBODY; RYANODINE RECEPTOR;

ADULT; ANTIBODY TITER; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; AUTOANTIBODIES; COMPLEMENT ACTIVATION; FEMALE; HUMAN; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGE; MUSCLE PROTEINS; MYASTHENIA GRAVIS; PROTEIN KINASES; RECEPTORS, CHOLINERGIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SUPPORT, NON-U.S. GOV'T; THYMOMA;

EID: 0034332951     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00394-5     Document Type: Article

References (36)

1. CA-antibody: an immunological marker of thymic neoplasia in myasthenia gravis?
2. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin
3. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis
4. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors
5. Novel genetic immunotoxins and intracellular antibodies for cancer therapy
6. The membrane attack complex of complement at the endplate in myasthenia gravis
7. Clinical heterogeneity of seronegative MG
8. Affinity of the interaction between Fc gamma receptor type III (Fc gamma RIII) and monomeric human IgG subclasses. Role of Fc gamma RIII glycosylation
9. Differences in IgG subclass do not affect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells
10. Antibodies to skeletal muscle in myasthenia gravis. Part 2. Prevalence in non-thymoma patients
11. Determination of acetylcholine receptor antibody in myasthenia gravis. Clinical usefulness and pathogenic implications
12. Modulation of acetylcholine receptor function in TE671 cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis
13. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome
14. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975 classical article
15. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to lesser extent on epitope patchiness, antibody affinity and complement concentration
16. Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmatic reticulum
17. Ryanodine receptor autoantibodies in myasthenia gravis patients with thymoma
18. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma
19. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis
20. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients
21. An assessment of changes in the complement level of myasthenic sera
22. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclass 1 and 3
23. Muscle autoantibodies in subgroups of myasthenia gravis patients
24. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases
25. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats
26. IgG subclasses. A review
27. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations
28. Ryanodine receptor antibodies are associated with severe myasthenia gravis
29. Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells
30. A therapeutic Trojan horse: intracellular antibodies
31. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls
32. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor
33. Antibody dependent cell-mediated cytotoxicity. An additional mechanism in human autoimmune myasthenia gravis
34. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1